Eli Lilly Buy Hold or Sell Recommendation

LLY -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Considering 30-days investment horizon, and your above average risk tolerance our recommendation regarding Eli Lilly And Company is 'Strong Buy'. Macroaxis provides Eli Lilly buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LLY positions. The advice algorithm takes into account all of Eli Lilly And available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from LLY buy-and-hold prospective. Please see also Eli Lilly Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Execute Advice
Sell Eli LillyBuy Eli Lilly
Strong Buy


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Eli Lilly And Company has a risk adjusted performance of 0.0779, jensen alpha of 0.1029, total risk alpha of 0.0447, sortino ratio of 0.0698 and treynor ratio of 0.2296
Macroaxis provides buy, hold, or sell suggestion on Eli Lilly And to complement and cross-verify current analyst consensus on Eli Lilly And Company. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Eli Lilly is not overpriced, please confirm all Eli Lilly And fundamentals including its Price to Book, Cash Flow from Operations, Z Score, as well as the relationship between Cash and Equivalents and Market Capitalization . Given that Eli Lilly And has Price to Earning of 13.69 , we urge you verify Eli Lilly And Company market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Eli Lilly Trading Alerts and Improvement Suggestions

Eli Lilly And has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial commitments
Over 81.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Payment of 4800 shares by Taurel Sidney of Eli Lilly subject to Rule 16b-3

Eli Lilly current analysts recommendations

Target Median Price121.50
Target Mean Price124.08
Recommendation Mean2.40
Target High Price145.00
Number Of Analyst Opinions12
Target Low Price93.00

Eli Lilly Returns Distribution Density

Mean Return0.14Value At Risk1.64
Potential Upside1.79Standard Deviation1.13
 Return Density 

Institutional Investors

Security TypeSharesValue
Lilly Endowment IncCommon Shares116.6 M13 B
Vanguard Group IncCommon Shares71 M7.9 B
Blackrock IncCommon Shares61.1 M6.8 B
Primecap Management CoCommon Shares42.8 M4.8 B
Wellington Management Group LlpCommon Shares39.7 M4.4 B
State Street CorpCommon Shares37.1 M4.2 B
Capital International InvestorsCommon Shares25.1 M2.8 B

Eli Lilly Greeks

Alpha over DOW
Beta against DOW=0.55
Overall volatility
Information ratio =0.07

Eli Lilly Volatility Alert

Eli Lilly And Company has relatively low volatility with skewness of -0.44 and kurtosis of 0.77. However, we advise all investors to independently investigate Eli Lilly And Company to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
 Better Than Average     
 Worse Than Average Compare Eli Lilly to competition

Eli Lilly Fundamental Vs Peers

FundamentalsEli LillyPeer Average
Return On Equity0.0001 (0.31) 
Return On Asset0.0007 (0.14) 
Profit Margin0.004277 (1.27) 
Operating Margin29.94 (5.51) 
Current Valuation112.95 B16.62 B
Shares Outstanding965.43 M571.82 M
Shares Owned by Insiders0.12 10.09 
Shares Owned by Institutions81.46 39.21 
Number of Shares Shorted10.55 M4.71 M
Price to Earning13.69 28.72 
Price to Book35.71 9.51 
Price to Sales4.23 11.42 
Revenue24.74 B9.43 B
Gross Profit18.13 B27.38 B
EBITDA7.41 B3.9 B
Net Income4.18 B570.98 M
Cash and Equivalents2.38 B2.7 B
Cash per Share2.61 5.01 
Total Debt16.43 B5.32 B
Debt to Equity575.10 48.70 
Current Ratio1.13 2.16 
Book Value Per Share10.33 1.93 K
Cash Flow from Operations3.73 B971.22 M
Short Ratio3.46 4.00 
Earnings Per Share7.93 3.12 
Price to Earnings To Growth1.96 4.89 
Number of Employees33.91 K18.84 K
Market Capitalization104.71 B19.03 B
Total Asset35.57 B29.47 B
Retained Earnings12.63 B9.33 B
Working Capital4.34 B1.48 B
Current Asset12.57 B9.34 B
   Payment of 4800 shares by Taurel Sidney of Eli Lilly subject to Rule 16b-3 [view details]
Search macroaxis.com